True histiocytic lymphoma

Ellis G. Levine, Curtis A. Hanson, Waclaw Jaszcz, Bruce A. Peterson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

It is likely that a significant number of cases of THL will continue to be misdiagnosed unless appropriate cytochemical and immunologic markers are incorporated into the panel of studies performed at diagnosis. The clinical findings are nonspecific. With the possible exception of skin infiltration, the frequency of symptoms and signs appear to approximate those of intermediate grade lymphomas. Most commonly, it is the histopathological features that suggest the histiocytic nature of a malignant process, but these alone are not sufficient to secure the diagnosis. Thus, in the absence of a clearly defined lymphoid origin, it is the detection of specific histiocytic markers that establishes a lymphoma as THL. Only the recognition and careful study of additional cases will potentially enable clinical investigators to identify any unique characteristics and distinguish this disease from other lymphomas. For the present, it would appear that the treatment indicated for a patient with diffuse large cell lymphoma would also be appropriate for a comparable patient with THL. Although longterm disease-free survival in THL is possible, there are presently inadequate data to estimate curability.

Original languageEnglish (US)
Pages (from-to)39-49
Number of pages11
JournalSeminars in Oncology
Volume18
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

Histiocytic Sarcoma
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Diagnostic Errors
Non-Hodgkin's Lymphoma
Disease-Free Survival
Signs and Symptoms
Biomarkers
Research Personnel
Skin
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Levine, E. G., Hanson, C. A., Jaszcz, W., & Peterson, B. A. (1991). True histiocytic lymphoma. Seminars in Oncology, 18(1), 39-49.

True histiocytic lymphoma. / Levine, Ellis G.; Hanson, Curtis A.; Jaszcz, Waclaw; Peterson, Bruce A.

In: Seminars in Oncology, Vol. 18, No. 1, 1991, p. 39-49.

Research output: Contribution to journalArticle

Levine, EG, Hanson, CA, Jaszcz, W & Peterson, BA 1991, 'True histiocytic lymphoma', Seminars in Oncology, vol. 18, no. 1, pp. 39-49.
Levine EG, Hanson CA, Jaszcz W, Peterson BA. True histiocytic lymphoma. Seminars in Oncology. 1991;18(1):39-49.
Levine, Ellis G. ; Hanson, Curtis A. ; Jaszcz, Waclaw ; Peterson, Bruce A. / True histiocytic lymphoma. In: Seminars in Oncology. 1991 ; Vol. 18, No. 1. pp. 39-49.
@article{7cc18526daab48e68ea34f6cdf27a025,
title = "True histiocytic lymphoma",
abstract = "It is likely that a significant number of cases of THL will continue to be misdiagnosed unless appropriate cytochemical and immunologic markers are incorporated into the panel of studies performed at diagnosis. The clinical findings are nonspecific. With the possible exception of skin infiltration, the frequency of symptoms and signs appear to approximate those of intermediate grade lymphomas. Most commonly, it is the histopathological features that suggest the histiocytic nature of a malignant process, but these alone are not sufficient to secure the diagnosis. Thus, in the absence of a clearly defined lymphoid origin, it is the detection of specific histiocytic markers that establishes a lymphoma as THL. Only the recognition and careful study of additional cases will potentially enable clinical investigators to identify any unique characteristics and distinguish this disease from other lymphomas. For the present, it would appear that the treatment indicated for a patient with diffuse large cell lymphoma would also be appropriate for a comparable patient with THL. Although longterm disease-free survival in THL is possible, there are presently inadequate data to estimate curability.",
author = "Levine, {Ellis G.} and Hanson, {Curtis A.} and Waclaw Jaszcz and Peterson, {Bruce A.}",
year = "1991",
language = "English (US)",
volume = "18",
pages = "39--49",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - True histiocytic lymphoma

AU - Levine, Ellis G.

AU - Hanson, Curtis A.

AU - Jaszcz, Waclaw

AU - Peterson, Bruce A.

PY - 1991

Y1 - 1991

N2 - It is likely that a significant number of cases of THL will continue to be misdiagnosed unless appropriate cytochemical and immunologic markers are incorporated into the panel of studies performed at diagnosis. The clinical findings are nonspecific. With the possible exception of skin infiltration, the frequency of symptoms and signs appear to approximate those of intermediate grade lymphomas. Most commonly, it is the histopathological features that suggest the histiocytic nature of a malignant process, but these alone are not sufficient to secure the diagnosis. Thus, in the absence of a clearly defined lymphoid origin, it is the detection of specific histiocytic markers that establishes a lymphoma as THL. Only the recognition and careful study of additional cases will potentially enable clinical investigators to identify any unique characteristics and distinguish this disease from other lymphomas. For the present, it would appear that the treatment indicated for a patient with diffuse large cell lymphoma would also be appropriate for a comparable patient with THL. Although longterm disease-free survival in THL is possible, there are presently inadequate data to estimate curability.

AB - It is likely that a significant number of cases of THL will continue to be misdiagnosed unless appropriate cytochemical and immunologic markers are incorporated into the panel of studies performed at diagnosis. The clinical findings are nonspecific. With the possible exception of skin infiltration, the frequency of symptoms and signs appear to approximate those of intermediate grade lymphomas. Most commonly, it is the histopathological features that suggest the histiocytic nature of a malignant process, but these alone are not sufficient to secure the diagnosis. Thus, in the absence of a clearly defined lymphoid origin, it is the detection of specific histiocytic markers that establishes a lymphoma as THL. Only the recognition and careful study of additional cases will potentially enable clinical investigators to identify any unique characteristics and distinguish this disease from other lymphomas. For the present, it would appear that the treatment indicated for a patient with diffuse large cell lymphoma would also be appropriate for a comparable patient with THL. Although longterm disease-free survival in THL is possible, there are presently inadequate data to estimate curability.

UR - http://www.scopus.com/inward/record.url?scp=0026090305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026090305&partnerID=8YFLogxK

M3 - Article

C2 - 1992523

AN - SCOPUS:0026090305

VL - 18

SP - 39

EP - 49

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -